u/line_petrov

Is this a prior authorisation denial or a formulary exclusion?

early fullness for the first eight days after each step, then nothing, every single time. Predictable enough that I started planning my week around it.

Has anything else changed in the same window?

holding a dose an extra month is a legitimate answer to bad tolerance

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

That criterion is from the previous plan year. The current bulletin has different wording.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

reflux at night, try not eating in the three hours before bed

swirl_dont_shake is right that the two molecules are not interchangeable.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

Are you comparing yourself with the trial mean or with the people who post the most?

the appetite effect is blunter than sema, in a good way, most weeks

Agree. The GIP component is the interesting half and it barely gets discussed outside c/glp1science.

Disagree. Severe abdominal pain is not on the list of things to wait out, and this board should not be treating it as one.

It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.

a rough fortnight at each step is normal, a rough three months is not

a peer-to-peer call is often faster than a written appeal

The fatigue turned out to be that I was eating about a third of what I thought I was.

lina_dziedzic is right about the timing. The day-of-week pattern is the diagnostic bit, not the severity.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

That advice is jurisdiction-specific and this board spans several. Say where you are.

a peer-to-peer call is often faster than a written appeal

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.

Nothing in this thread is medical advice, including this comment. I am describing a mechanism, not telling anybody what to do about their own week.

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

Internal appeals are decided by the plan. External review is decided by an independent body and, where it applies, its determination is binding. They are separate mechanisms and the second is chronically underused.

the formulary is published, read it before you appeal

pens and vials are the same molecule, the price is the difference

the second-level appeal is where things actually turn

2.5 is the starter dose and it is not meant to be the dose that works

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

Reconstituted or powder, and how long has it been in solution?

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

Right.

Agreed, with one qualifier: that is the mean of the top arm and the spread around it was enormous.

Research-use-only material is not approved for human use.

This. The step interval is a floor, and reading it as a timetable is the most expensive mistake in the thread.

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.